Meghan Malone-Moses

Thrombolysis in acute ischaemic stroke: time for a rethink?

As the UK regulator reviews alteplase in ischaemic stroke, Brian Alper and colleagues interpret the evidence to suggest increased mortality with uncertain benefit for its use beyond three hours

Authors’ reply to Wardlaw and Berge

Wardlaw and Berge note the use of data from all thrombolytic trials and alteplase trials, and that distinguishing between these conclusions could be a source of confusion.1 Either way, we question the validity of “up to six hours” or “up to 4.5 hours” conclusions because: